1.57
+0.085(+5.74%)
Currency In USD
| Previous Close | 1.48 |
| Open | 1.51 |
| Day High | 1.63 |
| Day Low | 1.51 |
| 52-Week High | 8.19 |
| 52-Week Low | 1.38 |
| Volume | 258,525 |
| Average Volume | 785,451 |
| Market Cap | 69.74M |
| PE | -1.03 |
| EPS | -1.52 |
| Moving Average 50 Days | 2.06 |
| Moving Average 200 Days | 3.17 |
| Change | 0.09 |
If you invested $1000 in Werewolf Therapeutics, Inc. (HOWL) since IPO date, it would be worth $97.2 as of January 02, 2025 at a share price of $1.565. Whereas If you bought $1000 worth of Werewolf Therapeutics, Inc. (HOWL) shares 3 years ago, it would be worth $128.07 as of January 02, 2025 at a share price of $1.565.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference
GlobeNewswire Inc.
Nov 20, 2024 1:00 PM GMT
WATERTOWN, Mass., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of conditionally activated therapeutics engineered to s
Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting
GlobeNewswire Inc.
Nov 07, 2024 2:02 PM GMT
- Interim phase 1 clinical trial update reveals the clinical potential of the tumor-activated IL-12 prodrug WTX-330, with favorable tolerability profile and encouraging efficacy signals - - Additional preclinical data demonstrate INDUKINETM molecules
Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire Inc.
Nov 07, 2024 2:00 PM GMT
– Interim data from ongoing Phase 1 clinical trial of WTX-330, further characterizing tolerability and activity profile, to be presented at SITC Annual Meeting – – Monotherapy and combination expansion arms open and enrolling in ongoing Phase 1/1b cl